Results 261 to 270 of about 586,499 (386)

The C-terminal 25 amino acids of the protease and its substrate ICP35 of herpes simplex virus type 1 are involved in the formation of sealed capsids [PDF]

open access: bronze, 1995
L Matusick-Kumar   +6 more
openalex   +1 more source

Genital Herpes [PDF]

open access: yesJournal of Midwifery & Women's Health, 2013
openaire   +2 more sources

The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1.

open access: yesJournal of General Virology, 1988
D. McGeoch   +8 more
semanticscholar   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus   +5 more
wiley   +1 more source

An off-target effect of BX795 blocks herpes simplex virus type 1 infection of the eye

open access: yesScience Translational Medicine, 2018
Dinesh Jaishankar   +7 more
semanticscholar   +1 more source

Targeting Genome Maintenance Defects of Cancers Using Chain‐Terminating Nucleoside Analogs

open access: yesCancer Science, EarlyView.
Nucleoside analogs interfere with DNA replication either by their chain‐terminating properties or by serving as DNA damage on the template. The genome maintenance pathways required to maintain cellular tolerance to each nucleoside analog vary depending on the drug.
Ryotaro Kawasumi   +2 more
wiley   +1 more source

Genital Herpes Zoster: A Report of a Rare Case [PDF]

open access: diamond
Sofia Kalantzi   +4 more
openalex   +1 more source

Tafasitamab as Monotherapy or in Combination in Japanese Patients With B‐Cell Non‐Hodgkin Lymphoma: Results From the Phase 1b J‐MIND Study

open access: yesCancer Science, EarlyView.
J‐MIND evaluated the safety and tolerability of tafasitamab, a CD19‐targeting monoclonal antibody, alone or in combination with other therapies in Japanese patients with B‐cell non‐Hodgkin lymphoma (NHL). Most common treatment‐emergent adverse events across all groups were hematological, and no serious tafasitamab treatment‐related or fatal adverse ...
Koji Izutsu   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy